Claudio Tiribelli

From Wikipedia, the free encyclopedia

Claudio Tiribelli
TiribelliClaudio.jpg
Born (1946-10-06) 6 October 1946 (age 75)
Venice, Italy
Children1 son
Scientific career
InstitutionsUniversity of Trieste
Fondazione Italiana Fegato - Italian Liver Foundation

Claudio Tiribelli (born 6 October 1946) is an Italian hepatologist best known for his studies on bilirubin and in particular on Kernicterus, a bilirubin-induced neurological damage.[1]

Biography[]

Claudio Tiribelli was born in Venice, Italy on 6 October 1946. He graduated summa cum laude in Medicine and Surgery at the University of Padua. During his Ph.D. he studied at the University of Trieste as research clinical fellow. In 1980 he started his activity as professor of medicine. From 1980 to 1985 he was assistant professor of medicine, from 1985 to 1988 research associate, from 1989 to 2008 he was professor of medicine, specializing in biochemistry applied to medicine, and 2008 he was appointed professor of gastroenterology at the University of Trieste, until his retirement in 2016. He was research fellow at the Department of Pharmacology, University of Groningen in 1982, a visiting scientist at Polytechnic University, New York, NY, USA in 1989, a visiting professor, University of Toronto, Canada in 1994. Since 2019, Tiribelli is visiting professor at Charles University, Prague Czech Republic.

Tiribelli also had an intense clinical activity. In 2001 he become director of the Liver Research Center of Trieste, and then in 2010 he became director of the Liver Clinical Center, based in the Trieste Teaching Hospital, where in 2013 he was appointed head of the entire medical department.[citation needed]

In 1980 Tiribelli created Fondo Studi Fegato (Liver Studies Found), which in 2008 became Fondazione Italiana Fegato - Italian Liver Foundation, a no-profit research institution focused on liver and hepatic diseases, based in Trieste with worldwide collaborations and exchanges of students and scientists. Tiribelli is scientific director of the foundation.[citation needed]

For his international scientific activity, in 2011 he was awarded of the Laurea Honoris Causa by the Favaloro University, Buenos Aires, Argentina, and the following year again he obtained the Laurea Honoris Causa from the Universidad Nacional de Rosario, Rosario, Argentina. In 2017 was awarded by the Ministry of Science, Technology and Productive Innovation of Argentina of the Premio de Cooperación Internacional en Ciencia, Tecnología e Innovación "Luis Federico Leloir" - Award for International Cooperation in Science, Technology and Innovation granted very selectively to foreign scientists who gave a great contribution to the scientific international cooperation – Premios Leloir.[citation needed]

Since 1972 Tiribelli is married with Rita Russo and has a son, Mario who is an associate professor of hematology at the University of Udine Medical School.[citation needed]

Scientific activity[]

Since the very beginning Tiribelli was fascinated by bilirubin,[2] the yellow compounds which gives the yellow color the sclera and skin when increased for genetic condition or clinical liver disorders. This love lasted all his scientific life and nor he is regarded as one of the few world experts in the field. Based on his expertise he founded Bilimetrix® which develop the firs point-of-care device to measure bilirubin in neonates preventing a timely diagnosis of severe neonatal jaundice and a proper treatment.

Due to his clinical activity, linked with research interests, he is active in translational activity in several liver disorders as fatty liver and hepatocellular carcinoma. Together with his longstanding research associate Stefano Bellentani he designed and performed the Dionysus Study,[3][4] the first project exploring the prevalence and incidence of liver diseases in the general population.

He is coordinating a large group of researchers (PostDocs, PhD fellows, senior researchers) located in the hub lab at the Italian Liver Foundation in Trieste and spread around the world. The international programs Claudio is coordinating forces him to cross the Equator 14 times in 2019 (before the COVID pandemic).

Fondazione Italiana Fegato – Italian Liver Foundation[]

In 1980 the Fondo Studi Fegato (Liver Studies Found) was founded, renamed in 2008 Fondazione Italiana Fegato ("FIF", Italian Liver Foundation) a no-profit organization primarily involved in the field of molecular research applied to the liver and its diseases (Translational Hepatology). FIF actively interacts with several national and international scientific organizations and hosts every year PhD and post-doctoral researchers, international fellow researchers, and undergraduate students from University. In 2020, the scientific production of the was 35 full papers, 21 reviews, and 2 book chapters.[citation needed]

Claudio is scientific director of the foundation and coordinates the scientific activity of the senior scientists and the main current research lines at the foundation, which are:

International cooperation[]

Major efforts have been also given to the international cooperation among FIF and liver research centers around the world. These activity led to the signature of operational MoUs with several countries as Mexico (), Brazil ), Vietnam (Vietnam National University, Ho Chi Minh City), India (ILBS Institute of Liver & Biliary Sciences), Indonesia (Eijkman Institute for Molecular Biology) among the others.

Of particular relevance the cooperation with Argentina elicited in the creation of the first center for criobiology in South America Centro Binacional (Argentina-Italia) de Investigaciones en Criobiología Clínica y Aplicada (CAIC) established in 2009, also due to a grant of the Region Friuli Venezia Giulia. CAIC was joined by the Liver Transplant Program of Fundacion Favaloro.[citation needed]

Another very active project is that involving DOST Department of Science and Technology and PCHRD Philippine Council for Research and Development of the Philippines, with the creation of PhD and sandwich fellowships for Filipino students at FIF and the creation of the Filipino Liver Network together with University of the Philippines in Manila.[citation needed]

Memberships[]

  • EASL - European Association for the Study of the Liver
  • AASLD - American Association for the Study Liver Diseases
  • IASL - International Association for the Study of the Liver
  • AIGO - Italian Association of Gastroenterology
  • AISF - Associazione Italiana Studio Fegato
  • SIB - Italian Society of Biochemistry
  • SIBIOC - Italian Society Clinical Chemistry & Biochemistry
  • APASL - Asian Pacific Association Study Liver

Editorials and international activities[]

Honors and awards[]

Scientific publications[]

Claudio has over 350 scientific publications,[5] some of his most cited are:

  • "Bilirubin-Induced Neurologic Damage — Mechanisms and Management Approaches"[1]
  • "Prevalence of chronic liver diseases in the general population of Northern Italy: The Dionysos study"[4]
  • "Prevalence And Risk Factors For Hepatic Steatosis In Northern Italy"[3]
  • "The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population"[6]
  • "Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis (NASH)"[7]
  • "Intestinal Integrity, the Microbiome and Inflammation"[8]

References[]

  1. ^ a b Watchko, Jon F.; Tiribelli, Claudio (21 November 2013). Ingelfinger, Julie R. (ed.). "Bilirubin-Induced Neurologic Damage — Mechanisms and Management Approaches". New England Journal of Medicine. 369 (21): 2021–2030. doi:10.1056/NEJMra1308124. ISSN 0028-4793. PMID 24256380.
  2. ^ "claudio tiribelli bilirubin - Search Results - PubMed". PubMed. Retrieved 11 August 2021.
  3. ^ a b Bellentani, Stefano; Saccoccio, Gioconda; Masutti, Flora; Crocè, Lory S.; Brandi, Giovanni; Sasso, Franco; Cristanini, Giovanni; Tiribelli, Claudio (18 January 2000). "Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy". Annals of Internal Medicine. 132 (2): 112–117. doi:10.7326/0003-4819-132-2-200001180-00004. ISSN 0003-4819. PMID 10644271. S2CID 25141053.
  4. ^ a b Bellentani, Stefano; Tiribelli, Claudio; Saccoccio, Gioconda; Sodde, Marino; Fratti, Nicoletta; De Martin, Christina; Christianini, Giovanni (1 December 1994). "Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study". Hepatology. 20 (6): 1442–1449. doi:10.1002/hep.1840200611. PMID 7982643. S2CID 9045590.
  5. ^ "tiribelli c - Search Results - PubMed". PubMed. Archived from the original on 1 May 2021. Retrieved 29 July 2021.
  6. ^ Bedogni, Giorgio; Bellentani, Stefano; Miglioli, Lucia; Masutti, Flora; Passalacqua, Marilena; Castiglione, Anna; Tiribelli, Claudio (2 November 2006). "The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population". BMC Gastroenterology. 6 (1): 33. doi:10.1186/1471-230X-6-33. ISSN 1471-230X. PMC 1636651. PMID 17081293.
  7. ^ Marra, Fabio; Gastaldelli, Amalia; Svegliati Baroni, Gianluca; Tell, Gianluca; Tiribelli, Claudio (22 January 2008). "Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis". Trends in Molecular Medicine. 14 (2): 72–81. doi:10.1016/j.molmed.2007.12.003. PMID 18218340.
  8. ^ Vítek, Libor; Tiribelli, Claudio (13 August 2020). Phimister, Elizabeth G. (ed.). "Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation". New England Journal of Medicine. 383 (7): 684–686. doi:10.1056/NEJMcibr2013250. ISSN 0028-4793. PMID 32786195.

 

Retrieved from ""